Fig. 1.
Mechanisms of immunotherapy combinations in gynecological cancers. Legend: Novel studies in gynecological cancers are combining checkpoint blockade with multiple therapies including traditional chemotherapy, PARP inhibitors, anti-VEGF agents, and anti-CTLA-4 antibodies, potentially targeting multiple mechanisms and overcoming resistance. Abbreviations: TCR T cell receptor, TKI tyrosine kinase inhibitor, RTK receptor tyrosine kinase, FRα folate receptor alpha